Targets › SLC19A3
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 4; Neurology, Ophthalmology, Psychiatry; next expected readout Jun 2027.
Mediates high affinity thiamine uptake, probably via a proton anti-port mechanism. Has no folate transport activity. (UniProt, Q9BZV2)
Open in Phaseline: the race on SLC19A3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Thammasat University | Benfotiamine Lipophilic thiamine derivative (fat-soluble form of vitamin B1) | SLC19A3 | Phase 4 | Diabetic Peripheral Neuropathy (DPN) | Jun 2027 |
| Columbia University | Nicotinamide and Pyruvate NAD+ precursor and mitochondrial energy substrate | SLC19A3 | Phase 2 | Primary Open Angle Glaucoma | Aug 2027 |
| Institut National de la Santé Et de la Recherche Médicale, France | Thiamine Thiamine supplementation to reduce brain injury and cognitive impairment associated with c | SLC19A2, SLC19A3 | Phase 2 | Alcohol Use Disorder | Oct 2027 |
Diabetic Peripheral Neuropathy (DPN) (1) Primary Open Angle Glaucoma (1) Alcohol Use Disorder (1)
small molecule (3)
Thammasat University (1) Columbia University (1) Institut National de la Santé Et de la Recherche Médicale, France (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.